Sequential therapy of Helicobacter pylori in Korea

Sequential therapy of Helicobacter pylori in Korea: a multicenter prospective randomized controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0000378

Enrollment

656

Registered

2012-03-08

Start date

2012-03-05

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : a. standard triple therapy: standard dose of PPI (omeprazole 20 mg, lansoprazole 30 mg, pantoprazole 40 mg, rabeprazole 20 mg, esomeprazole 20 mg), amoxicillin 1.0 g, clarithromycin 500 mg bid

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. H. pylori positive peptic ulcers including scar 2. H. pylori positive low grade mucosa-associated lymphoid tissue lymphoma (B cell type) of stomach 3. H. pylori positive early gastric adenocarcinoma after endoscopic resection

Exclusion criteria

Exclusion criteria: 1. Previous history of H. pylori eradiation 2. Severe hepatopathy, nephropathy, cardiac diseases, lung diseases and other systemic diseases 3. Pregnant patients and a possiblity of pregnancy during study period 4. When investigators decided that the patients are inadequate for this study

Design outcomes

Primary

Measure	Time frame
Eradiation rate	—

Secondary

Measure	Time frame
adverse events;compliance	—

Countries

Korea, Republic of

Contacts

Public ContactByung Wook Kim

The Catholic University of Korea, Incheon St. Mary's Hospital

bleok@naver.com+82-32-280-5052

Outcome results